Johnson & Johnson (NYSE:JNJ) Set to Announce Quarterly Earnings on Tuesday

Xavier Trudeau
Juillet 17, 2017

Liberty Capital Management Inc. now owns 7,226 shares of the company's stock valued at $900,000 after buying an additional 50 shares during the period. Johnson & Johnson makes up 3.2% of Ipswich Investment Management Co.

Sns Financial Group Llc increased Johnson & Johnson (JNJ) stake by 123.41% reported in 2016Q4 SEC filing. It improved, as 63 investors sold JNJ shares while 834 reduced holdings. Berson & Corrado Investment Advisors LLC boosted its position in Johnson & Johnson by 0.7% in the first quarter. State Street Corp now owns 153,566,950 shares of the company's stock worth $17,692,455,000 after buying an additional 4,892,277 shares during the last quarter. L P now owns 110,823 shares of the company's stock worth $12,768,000 after buying an additional 88,510 shares during the last quarter. Jackson Grant Investment Advisers Inc. increased its stake in Johnson & Johnson by 7.3% in the fourth quarter. After $0.78 actual EPS reported by Masonite International Corp for the previous quarter, Wall Street now forecasts 42.31% EPS growth. Burke & Herbert Bank & Trust Co. increased its stake in Johnson & Johnson by 2.6% in the first quarter. The expected JNJ's profit could reach $4.82 billion giving the stock 18.62 P/E in the case that $1.78 earnings per share is reported. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main acquired a new position in Johnson & Johnson during the fourth quarter worth $277,294,000. Lenox Wealth Advisors Inc. now owns 871 shares of the company's stock valued at $108,000 after buying an additional 6 shares during the period. Johnson & Johnson comprises about 1.6% of Quotient Investors LLC's holdings, making the stock its 9th largest position. BMO Capital Markets reaffirmed a buy rating and issued a $132.00 price objective on shares of Johnson & Johnson in a report on Friday, June 2nd. The stock had a trading volume of 4,383,133 shares. The stock has a market cap of $357.20 billion, a price-to-earnings ratio of 22.29 and a beta of 0.78. The stock's 50-day moving average price is $130.42 and its 200 day moving average price is $122.68. More interesting news about Johnson & Johnson (NYSE:JNJ) were released by: Fool.com and their article: "Here's Why Johnson & Johnson Is Valued at Its Highest P/E in a Decade" published on July 07, 2017 as well as Theguardian.com's news article titled: "Johnson & Johnson doubts vaginal mesh implants cause chronic pain, court hears" with publication date: July 12, 2017.

The stock of Johnson & Johnson (NYSE:JNJ) earned "Outperform" rating by RBC Capital Markets on Wednesday, July 20. They expect $1.11 EPS, up 8.82% or $0.09 from last year's $1.02 per share. Johnson & Johnson had a net margin of 24.89% and a return on equity of 25.20%. The business had revenue of $17.77 billion for the quarter, compared to the consensus estimate of $18.02 billion. The Sns Financial Group Llc holds 11,537 shares with $1.33M value, up from 5,164 last quarter.

ILLEGAL ACTIVITY NOTICE: This news story was posted by Markets Daily and is the sole property of of Markets Daily. If you are reading this story on another site, it was copied illegally and reposted in violation of United States and worldwide copyright & trademark law. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/07/16/cornerstone-financial-partners-llc-sells-1025-shares-of-johnson-johnson-jnj-updated-updated.html.

Several equities analysts recently weighed in on the company. BidaskClub downgraded shares of Johnson & Johnson from a strong-buy rating to a buy rating in a report on Saturday, July 1st. Vetr cut shares of Johnson & Johnson from a "buy" rating to a "hold" rating and set a $128.54 price objective on the stock.in a research note on Monday, May 1st. Finally, Jefferies Group LLC restated a "hold" rating and issued a $145.00 price objective (up from $140.00) on shares of Johnson & Johnson in a report on Friday. Finally, Morgan Stanley lifted their price objective on shares of Johnson & Johnson from $135.00 to $140.00 and gave the company an "overweight" rating in a research report on Wednesday, July 5th. Eleven research analysts have rated the stock with a hold rating and ten have given a buy rating to the company's stock. The stock now has a consensus rating of "Hold" and a consensus target price of $133.65.

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. The Company's primary focus is products related to human health and well-being.

D'autres rapports CampDesrEcrues

Discuter de cet article

SUIVRE NOTRE JOURNAL